Altuvoct

Altuvoct is a pharmaceutical product containing Efanesoctocog Alfa, designed for intravenous use. It is used to manage certain medical conditions related to blood clotting. This medication is manufactured by Swedish Orphan Biovitrum Ab (Publ) and is available in the EU market.

Altuvoct, containing the active ingredient Efanesoctocog Alfa, is primarily used for the treatment of hemophilia B. This condition is characterized by a deficiency in clotting factor IX, leading to prolonged bleeding episodes. The medication works by replacing the missing clotting factor, helping to control and prevent bleeding episodes. What is Altuvoct used for? It is used to manage bleeding episodes and to prevent bleeding in individuals with hemophilia B.

Common effects of Altuvoct may include localized reactions at the injection site, such as redness, swelling, or discomfort. Some individuals may experience mild to moderate headaches or flu-like symptoms. These effects are generally temporary and should subside as the body adjusts to the medication. If any severe or persistent effects occur, it is important to consult a healthcare provider.

Altuvoct should be handled with care and administered under the supervision of a healthcare professional. It is important to inform your healthcare provider about any allergies or pre-existing conditions before starting treatment. Proper storage and handling instructions should be followed to maintain the efficacy of the medication. Always follow the prescribed guidelines for administration to ensure safety and effectiveness.

Altuvoct may interact with certain medications, including those that affect blood clotting. It is important to inform your healthcare provider about all medications you are currently taking to avoid potential interactions. Alcohol and other substances that affect blood clotting should be used with caution. Always consult a healthcare provider before starting or stopping any medication while using Altuvoct.